HAZLET, N.J. - eTradeWire -- In this program, experts will 1) identify HF medications that increase the risk for hyperkalemia, 2) emphasize the importance of patients taking RAASi therapy and at target doses, 3) discuss the clinical evidence for using novel potassium binders for the treatment of hyperkalemia, and their potential impact in facilitating optimization of RAASi therapy to reduce patient cardiovascular risk, and 4) explain the rationale for using novel potassium binders in long-term management.

The educational objectives include:

• Recognize hyperkalemia as a frequent, treatable, and manageable side effect of optimal HF therapy
• Describe the relationship between down-titration or discontinuation of RAASi therapy and clinical outcomes
• Discuss the clinical evidence for novel potassium binders in the treatment of hyperkalemia

Click here for more information

More on eTradeWire News

• Fibroid Pandemic Hosts 4th Annual RUN F.A.R. 5K July 26 in Atlanta
• Love Fellowship Church to Host Community Outreach Day on July 20, 2025 at Plus Park Collective
• International Hypnosis Association Approves Online Hypnotherapy Certification from Michigan-Based Trainer
• Food Journal Magazine Launches as the Ultimate Guide to Food Festivals and Culinary Culture
• Food and Ag Lab LLC Stands Alone as Texas's Only ISO 17025-Accredited Lab for Gluten Testing

CHAIR
Mikhail Kosiborod, MD
Vice President of Research
Saint Luke's Health System
Professor of Medicine
University of Missouri-Kansas City
Kansas City, Missouri

FACULTY
Akshay Desai, MD, MPH
Director, Cardiomyopathy and Heart Failure Program
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Anuradha Lala-Trindade, MD
Associate Professor of Medicine
Associate Professor of Population Health Science and Policy
Ichan School of Medicine at Mount Sinai
New York, New York

Orly Vardeny, PharmD
Associate Professor of Medicine
University of Minnesota
Medical School
Minneapolis, Minnesota

This educational activity is intended for clinicians who manage patients with heart failure.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia LLC designates this live activity for a maximum of 1.25 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1.25 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

More on eTradeWire News

• Prestige Commercial Capital Unveils CoreRate Preferred Funding for Small Business Growth in 2025
• Country Star Colin Stough to Headline Private Live Concert at Sea This October 2025
• Webb Shadle Public Library Awarded $10,000 National Grant to Enhance Virtual Accessibility
• Webb Shadle Public Library to Host Annual Pet Show, Sponsored by Carlisle Veterinary Clinic
• Leadership in the United States by Peter M Fiorillo